SGLT-2 inhibitor is an abbreviation for sodium-glucose cotransporter-2 inhibitors. SGLT-2 inhibitors are a class of medicine used to lower high blood glucose levels in people with type 2 diabetes. They may also be called gliflozins.
SGLT-2 inhibitors inhibit SGLT-2 proteins located in the renal tubules of the kidneys which are responsible for reabsorbing glucose back into the blood. As a result, more glucose is excreted in the urine. SGLT-2 inhibitors have been shown to be effective at lowering hemoglobin A1c levels, improving weight loss and lowering blood pressure. They carry a low risk of hypoglycemia (low blood sugar levels).
They are usually well tolerated. SGLT-2 inhibitors may be used in the treatment of type 2 diabetes and act independently of beta-cell function in the pancreas.
Name | Updated |
---|---|
Canagliflozin (Canagliflozin [ kan-a-gli-floe-zin ]) | 16-Aug-2023 |
Bexagliflozin (Bexagliflozin [ bex-a-gli-floe-zin ]) | 16-Aug-2023 |
Ertugliflozin (Ertugliflozin [ er-too-gli-floe-zin ]) | 11-Aug-2023 |
Steglatro (Ertugliflozin [ er-too-gli-floe-zin ]) | 14-Jul-2023 |
Brenzavvy (Bexagliflozin) | 13-Jul-2023 |
Jardiance (Empagliflozin [ em-pa-gli-floe-zin ]) | 11-Jul-2023 |
Invokana (Canagliflozin [ kan-a-gli-floe-zin ]) | 10-Jul-2023 |
Farxiga (Dapagliflozin) | 10-Jul-2023 |
Empagliflozin (Empagliflozin [ em-pa-gli-floe-zin ]) | 10-Jul-2023 |
Dapagliflozin (Dapagliflozin) | 10-Jul-2023 |